|
|
The prostate-specific antigen check is now a routine part of most cancers screening programs. The test allows for earlier detection, monitoring of therapy response and prediction of disease recurrence. Elevated levels of prostate-specific antigen in the blood counsel enlargement or tumors of the prostate, which may be confirmed by ultrasound test and biopsy. Since prostate tumors can develop rapidly and unfold to different components of the body, early detection is crucial. The FDA authorised the primary PSA check in 1986 for monitoring patients already diagnosed with prostate cancer. A pivotal study in the April 25, 1991, issue of the brand new England Journal of Medicine established that the PSA test, mixed with rectal examination or ultrasonography, provides an efficient method of detecting prostate cancer. In August 1994, the FDA authorised the Tandem® brand PSA test for use with rectal examination to help detection of prostate most cancers in males age 50 and older.
Here is my web blog: BloodVitals wearable |
|
发表于